TABLE 1.
List of corrinated peptides tested in the context of energy balance and diabetes preclinical models
| Corrination moiety | Peptide/protein | In vivo model | Mode of administration | Key outcomes | Reference |
|---|---|---|---|---|---|
| B12 | Insulin | Rat | Oral | Prolonged hypoglycaemic activity and increased half‐life | (Petrus et al., 2007) |
| B12 | Ex4 |
Rat Mouse Shrew |
s.c., i.p. and i.c.v. | Maintained glucoregulation, no effect on food intake and body weight, and near absence of emetic events | (Borner, Shaulson, et al., 2020; Mietlicki‐Baase et al., 2018) |
| B12 | PYY3–36 | Rat | s.c. | Augmented hypophagia and weight loss | (Henry et al., 2015) |
| IF‐B12 | Ex4 | Not tested | Not applicable | Increased gut and kidney protease resistance | (Bonaccorso et al., 2015) |
| Cbi | Ex4 |
Rat Shrew |
i.p. | Improved glycaemic response in IPGTT and reduction of emetic events | (Borner, Workinger, et al., 2020) |
Abbreviations: B12, vitamin B12; Cbi, cobinamide; Ex4, exendin‐4; IF, intrinsic factor; IPGTT, intraperitoneal glucose tolerance test.